Persistence of a clone of glycopeptide-resistant Enterococcus faecalis among patients in an intensive care unit of a Greek hospital

Journal of Antimicrobial Chemotherapy

Volumn 53, Issue 1, 2004, Pages 109-112

  Pournaras, Spyros ^a   Malamou Lada, Helen ^b   Mylona Petropoulou, Dimitra ^b   Vagiakou Voudris, Helen ^b   Tsakris, Athanassios ^c   Maniatis, Antonios N ^a  

^a UNIVERSITY OF THESSALY   (Greece)

^b G GENNIMATAS GENERAL HOSPITAL   (Greece)

^c UNIVERSITY OF ATHENS   (Greece)

Author keywords

Enterococcus faecalis clone; Glycopeptide resistance; Outbreak

Indexed keywords

AMPICILLIN; CEPHALOSPORIN; CHLORHEXIDINE; CIPROFLOXACIN; CLINDAMYCIN; ERYTHROMYCIN; GENTAMICIN; METRONIDAZOLE; PENICILLIN G; POLYPEPTIDE ANTIBIOTIC AGENT; STREPTOMYCIN; TEICOPLANIN; TETRACYCLINE; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL GENE; BACTERIAL INFECTION; BACTERIUM ISOLATE; BACTERIUM ISOLATION; CLONE; CONTROLLED STUDY; DISEASE SEVERITY; ENTEROCOCCUS FAECALIS; GREECE; HOSPITAL; INFECTION CONTROL; INTENSIVE CARE UNIT; MATING; NONHUMAN; PLASMID; POLYMERASE CHAIN REACTION; PULSED FIELD GEL ELECTROPHORESIS; RESTRICTION MAPPING; WARD;

ANTI-BACTERIAL AGENTS; CROSS INFECTION; DNA, BACTERIAL; DRUG RESISTANCE, BACTERIAL; ELECTROPHORESIS, GEL, PULSED-FIELD; ENTEROCOCCUS FAECALIS; GENES, BACTERIAL; GLYCOPEPTIDES; GRAM-POSITIVE BACTERIAL INFECTIONS; GREECE; HUMANS; INTENSIVE CARE UNITS; MICROBIAL SENSITIVITY TESTS; POLYMERASE CHAIN REACTION;

EID: 0347917222     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/dkh035     Document Type: Article

References (10)

1. Low, D. E., Keller, N., Barth, A. et al. (2001). Clinical prevalence, antimicrobial susceptibility, and geographic resistance patterns of enterococci: results from the SENTRY antimicrobial surveillance program, 1997-1999. Clinical Infectious Diseases 32, Suppl. 2, 133-45.
2. Rice, L. B. (2001). Emergence of vancomycin-resistant enterococci. Emerging Infectious Diseases 7, 183-7.
3. Hayden, M. K. (2000). Insights into the epidemiology and control of infection with vancomycin-resistant enterococci. Clinical Infectious Diseases 31, 1058-65.
4. Biavasco, F., Miele, A., Vignaroli, C. et al. (1996). Genotypic characterization of a nosocomial outbreak of VanA Enterococcus faecalis. Microbial Drug Resistance 2, 231-7.
5. Maniatis, A. N., Pournaras, S., Kanellopoulou, M. et al. (2001). Dissemination of clonally unrelated erythromycin- and glycopeptide-resistant Enterococcus faecium isolates in a tertiary Greek hospital. Journal of Clinical Microbiology 39, 4571-4.
6. National Committee for Clinical Laboratory Standards. (2003). Performance Standards for Antimicrobial Susceptibility Testing - Thirteenth Informational Supplement M100-S13, Table 2D. NCCLS, Wayne, PA, USA.
7. Fines, M., Perichon, B., Reynolds, P. et al. (1999). VanE, a new type of acquired glycopeptide resistance in Enterococcus faecalis BM4405. Antimicrobial Agents and Chemotherapy 43, 2161-4.
8. Morrison, D., Woodford, N., Barrett, S. P. et al. (1999). DNA banding pattern polymorphism in vancomycin-resistant Enterococcus faecium and criteria for defining strains. Journal of Clinical Microbiology 37, 1084-91.
9. Woodford, N., Morrison, D., Cookson, B. et al. (1993). Comparison of high-level gentamicin-resistant Enterococcus faecium isolates from different continents. Antimicrobial Agents and Chemotherapy 37, 681-4.
10. Noskin, G. A., Stosor, V., Cooper, I. et al. (1995). Recovery of vancomycin-resistant enterococci on fingertips and environmental surfaces. Infection Control and Hospital Epidemiology 16, 577-81.